このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Medifast マネジメント

マネジメント基準チェック /34

Medifast'sの CEO はDan Chardで、 Oct2016年に任命され、の在任期間は 7.67年です。の年間総報酬は$ 7.04Mで、 14.2%給与と85.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.4%を直接所有しており、その価値は$ 3.21M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と7.7年です。

主要情報

Dan Chard

最高経営責任者

US$7.0m

報酬総額

CEO給与比率	14.2%
CEO在任期間	7.7yrs
CEOの所有権	1.4%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	7.7yrs

経営陣の近況

Recent updates

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Aug 09

Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

Jul 27

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Jul 12

Medifast And Its Real Value

Jun 24

Medifast: Growth And Value At A Reasonable Price

May 17

CEO報酬分析

Medifast の収益と比較して、Dan Chard の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m
Sep 30 2018	n/a	n/a	US$47m
Jun 30 2018	n/a	n/a	US$40m
Mar 31 2018	n/a	n/a	US$34m
Dec 31 2017	US$2m	US$650k	US$28m

報酬と市場: Danの総報酬 ($USD 7.04M ) は、 US市場 ($USD 1.53M ) の同規模の企業の平均を上回っています。

報酬と収益: Danの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dan Chard (59 yo)

7.7yrs

在職期間

US$7,039,062

報酬

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel Chard	Executive Chairman & CEO	7.7yrs	US$7.04m	1.4% $ 3.0m
James Maloney	Chief Financial Officer	3.9yrs	US$2.01m	0.069% $ 147.8k
Anthony Tyree	Chief Business Operations Officer	2.4yrs	US$1.61m	0.074% $ 158.7k
Jason Groves	Executive VP	12.6yrs	US$1.63m	0.073% $ 158.1k
Nicholas Johnson	Chief Field Operations Officer	5.3yrs	US$1.70m	0.061% $ 132.5k
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	2.8yrs	データなし	0.0050% $ 10.7k
Steven Zenker	Vice President of Investor Relations	1.3yrs	データなし	データなし
Claudia Greninger	Chief Human Resources Officer	4.7yrs	データなし	データなし

4.3yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: MEDの経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Daniel Chard	Executive Chairman & CEO	7.7yrs	US$7.04m	1.4% $ 3.0m
Jeffrey Brown	Lead Independent Director	9yrs	US$263.42k	0.063% $ 135.5k
George Bray	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Hoer	Independent Director	6yrs	US$249.72k	0.049% $ 105.9k
Andrea Thomas	Independent Director	5yrs	US$249.72k	0.029% $ 63.1k
John Foreyt	Member of Scientific Advisory Board	no data	データなし	データなし
Ming Xian	Independent Director	6yrs	US$219.61k	データなし
Lawrence Cheskin	Chairman of Scientific Advisory Board	15.6yrs	データなし	データなし
Sylvia Rowe	Member of Scientific Advisory Board	no data	データなし	データなし
Scott Schlackman	Independent Director	9yrs	US$252.44k	0.043% $ 93.3k
John Hayes	Member of Scientific Advisory Board	no data	データなし	データなし
Mark Messina	Member of Scientific Advisory Board	no data	データなし	データなし

7.7yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: MEDの取締役会は経験豊富であると考えられます ( 7.7年の平均在任期間)。

Medifast マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Lead Independent Director notifies of intention to sell stock

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Independent Director notifies of intention to sell stock

Insufficient new directors

Recent updates

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 15% to US$21.25

Medifast: Significant Undervaluation Even As Struggles Persist

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Investor sentiment deteriorates as stock falls 25%

Consensus EPS estimates fall by 54%

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

First quarter 2024 earnings: EPS misses analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Medifast: Cheap Valuation, Uncertain Future

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Medifast Is Getting Attractive

Investor sentiment deteriorates as stock falls 17%

Consensus revenue estimates fall by 15%

New major risk - Revenue and earnings growth

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2023 earnings: EPS misses analyst expectations

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Price target decreased by 14% to US$62.50

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Investor sentiment deteriorates as stock falls 16%

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Consensus EPS estimates increase by 11%, revenue downgraded

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Now 21% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Lead Independent Director notifies of intention to sell stock

Price target decreased by 14% to US$80.00

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Price target increased by 31% to US$93.00

Medifast Unveils New Product Line, Optavia Active

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Now 20% undervalued after recent price drop

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast: In Survival Mode Against Diet Pills And The Recession

Medifast Holds Value During Headwinds

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Consensus EPS estimates fall by 25%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Full year 2022 earnings: EPS exceeds analyst expectations

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Medifast declares $1.64 dividend

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Price target decreased to US$106

Insufficient new directors

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

マネジメント基準チェック /34